CollPlant Biotechnologies Acquires Lightsolver for Strategic Entry Into Photonic Computing

The Quick Take

• CollPlant Biotechnologies (CLGN) is acquiring Lightsolver, entering high-performance photonic computing
• Photonic computing uses light instead of electrons to process data, offering potential speed and energy efficiency gains
• The acquisition represents a significant strategic diversification from plant-based regenerative medicine
• Management discussed cross-disciplinary applications and standalone commercial potential in the investor transcript

CollPlant Biotechnologies' acquisition of Lightsolver is an unusual corporate strategy move: a plant-based regenerative medicine company acquiring a photonic computing startup. Lightsolver develops optical computing hardware that uses photons rather than electrons to perform calculations, a technology promising advantages in specific workloads including optimization problems, AI inference, and scientific simulation. CollPlant's stated rationale involves both the standalone commercial potential of photonic computing and possible integration with its biologically-focused research infrastructure, representing a significant expansion of corporate scope.

Photonic computing occupies an interesting inflection point in the deep tech landscape. Companies like PsiQuantum, LightMatter, and Lightelligence have attracted significant venture funding with promises of speed and energy efficiency advantages over conventional silicon architectures. Lightsolver's approach to optical computing for optimization and constraint-satisfaction problems has drawn attention in the Israeli deep tech community. For CLGN investors, the acquisition raises legitimate questions about management focus and capital allocation: does diversifying into photonics strengthen the core regenerative medicine business or dilute focus from commercializing existing therapeutic assets?

Synthesized from 1 source.